Health Care & Life Sciences » Pharmaceuticals | Pieris Pharmaceuticals Inc.

Pieris Pharmaceuticals Inc. | Mutual Funds

Mutual Funds that own Pieris Pharmaceuticals Inc.

Name
Shares Held
% Shares Out
Change In Shares
% of Assets
As of Date
Tekla Healthcare Investors
1,297,531
2.4%
-609,610
0.65%
12/31/2017
iShares Russell 2000 ETF
1,086,776
2%
-579
0.01%
09/06/2018
Tekla Life Sciences Investors
563,608
1.04%
-265,583
0.64%
12/31/2017
iShares Russell 2000 Growth ETF
508,996
0.94%
0
0.03%
09/06/2018
CREF Stock Account
407,426
0.75%
7,916
0%
03/31/2018
LO Funds - Fundamental Equity Long/Short Syst. Hdg. Seed.
351,560
0.65%
-758
0.41%
09/30/2017
American Century Small Company Fund
251,921
0.47%
233,721
0.2%
06/30/2018
226,241
0.42%
125,000
0.1%
03/31/2018
Goldman Sachs Small Cap Growth Insights Fund
226,195
0.42%
126,258
0.16%
04/30/2018
Source Markets Plc - Morningstar US Energy Infrastracture
184,224
0.34%
184,224
0.14%
06/29/2018

About Pieris Pharmaceuticals

View Profile
Address
255 State Street
Boston Massachusetts 02109
United States
Employees -
Website http://www.pieris.com
Updated 07/08/2019
Pieris Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company, which engages in the discovery and development of Anticalin class of biotherapeutics. It offers technology to create differentiated drugs that can help patients suffering from cancer, severe asthma, anemia, and other medical conditions with an unmet medical need. The company was founded by Claus Schalper and Arne Skerra in 2001 and is headquartered in Boston, MA.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.